Morepen Laboratories

62.63
+0.58
(0.93%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
3,400.10 Cr
EPS
1.88
PE Ratio
27.22
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
100.90
52 Week Low
42.00
PB Ratio
3.09
Debt to Equity
0.03
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Morepen Laboratories: CDSCO Approves Studies for Fatty Liver Drug Resmetirom16 hours ago
Morepen Laboratories received CDSCO approval to conduct bioequivalence studies for Resmetirom, a drug treating non-alcoholic steatohepatitis (NASH). The company plans to start clinical trials and is considering out-licensing opportunities. The global NASH treatment market is expected to grow from $2.5 billion in 2024 to over $16 billion by 2032.
positive
Morepen Laboratories: Receives Approval for Resmetirom Bioequivalence Studies20 hours ago
Morepen Laboratories has obtained CDSCO approval to conduct bioequivalence studies for Resmetirom tablets, a potential NASH treatment, in 60mg, 80mg, and 100mg dosages. This positions Morepen among the first Indian pharma companies ready for the drug's global launch. The global NASH treatment market is projected to grow from $2.5 billion in 2024 to over $16 billion by 2032.
positive
Morepen Labs to Launch New Fatty Liver Drug Resmetirom21 hours ago
Morepen Laboratories has announced plans to introduce Resmetirom, a novel medication for the treatment of fatty liver disease. This move represents a significant expansion of the company's pharmaceutical portfolio and could potentially address a growing health concern.
View more
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,805.50
#1 4,41,861.50
36.71
#1 49,887.20
12.06
#1 9,648
13.77
59.04
6,108.00
1,59,984.60
78.50
8,184.00
0.89
1,600
#1 64.53
60.56
1,541.50
1,25,592.20
24.94
26,520.70
14.17
4,155
47.38
58.71
3,322.70
1,12,871.60
60.37
10,785.70
11.59
1,656
13.54
58.74
2,556.90
1,05,636.60
51.68
10,615.60
19.57
1,942
-16.38
59.78
1,176.00
1,00,026.20
#1 18.27
28,905.40
12.36
5,578
1.69
53.18
2,067.10
96,120.10
32.90
20,141.50
#1 19.94
1,936
38.82
53.30
888.05
89,207.70
19.71
19,831.50
13.82
3,831
29.92
52.81
1,209.60
72,437.60
19.93
29,559.20
17.55
3,169
-10.04
55.67
30,100.00
63,280.40
47.92
6,097.20
10.80
1,201
16.01
50.02
Growth Rate
Revenue Growth
19.72 %
Net Income Growth
149.61 %
Cash Flow Change
180.48 %
ROE
121.79 %
ROCE
113.54 %
EBITDA Margin (Avg.)
68.27 %

Quarterly Financial Results

Quarterly Financials
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
132
151
156
172
164
174
215
220
203
216
235
208
259
340
310
291
388
398
399
372
303
404
350
367
404
425
449
427
459
443
458
Expenses
121
130
137
154
152
157
195
197
184
198
215
188
231
305
278
256
343
353
364
350
288
374
328
348
375
388
394
375
404
394
417
EBITDA
11
20
19
18
12
17
19
23
20
18
20
21
28
36
33
35
45
45
35
22
16
30
22
19
29
37
55
53
55
49
41
Operating Profit %
7 %
13 %
12 %
10 %
7 %
10 %
8 %
10 %
10 %
7 %
7 %
9 %
10 %
9 %
10 %
11 %
11 %
11 %
8 %
5 %
5 %
7 %
6 %
4 %
7 %
8 %
11 %
11 %
11 %
10 %
8 %
Depreciation
9
8
8
10
9
10
10
11
12
8
9
9
8
8
8
7
7
7
7
7
7
7
7
7
8
8
8
10
6
2
4
Interest
1
1
1
1
0
0
0
1
0
0
1
1
0
0
1
-0
0
-9
1
1
0
1
1
1
0
1
2
1
1
1
1
Profit Before Tax
1
11
10
7
3
7
9
11
8
9
11
11
20
28
24
28
39
47
27
14
8
22
14
11
21
29
44
42
48
46
35
Tax
0
0
0
0
0
-0
0
0
0
5
0
0
0
0
0
1
8
10
6
2
3
7
5
3
6
7
12
14
12
11
9
Net Profit
1
11
10
7
3
7
9
11
8
4
11
11
19
27
24
27
31
37
22
12
6
16
9
8
15
21
32
29
36
35
27
EPS in ₹
0.03
0.25
0.23
0.15
0.05
0.16
0.20
0.23
0.17
0.09
0.24
0.25
0.43
0.60
0.53
0.59
0.68
0.83
0.48
0.27
0.12
0.33
0.15
0.16
0.29
0.42
0.63
0.54
0.71
0.65
0.49

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
489
524
538
586
615
664
858
1,070
1,111
1,293
Fixed Assets
323
297
272
264
236
216
225
252
267
307
Current Assets
115
157
192
243
300
372
527
734
756
889
Capital Work in Progress
0
0
0
0
0
0
2
14
17
25
Investments
0
0
0
0
0
1
1
0
0
1
Other Assets
167
227
267
321
379
446
631
804
827
960
Total Liabilities
489
524
538
586
615
664
858
1,070
1,111
1,293
Current Liabilities
128
167
325
340
339
351
404
457
321
402
Non Current Liabilities
74
58
18
20
23
28
30
36
37
44
Total Equity
287
300
196
226
253
284
424
578
752
847
Reserve & Surplus
78
91
106
136
163
194
291
457
651
745
Share Capital
210
210
90
90
90
90
90
96
102
102

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-0
-5
3
-1
4
4
28
-26
6
-5
Investing Activities
-32
-27
-14
-27
-13
-13
-70
-32
-47
-83
Operating Activities
51
50
41
63
17
11
51
-60
-91
73
Financing Activities
-19
-27
-24
-38
-0
6
47
66
144
5

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
May 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
34.54 %
34.54 %
34.54 %
34.54 %
38.38 %
36.74 %
36.74 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
38.22 %
35.65 %
35.65 %
35.65 %
35.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.29 %
0.00 %
1.85 %
1.67 %
7.72 %
2.08 %
2.22 %
1.94 %
DIIs
2.89 %
2.03 %
1.26 %
1.16 %
1.07 %
4.07 %
4.07 %
3.60 %
3.74 %
2.93 %
2.33 %
2.28 %
2.00 %
2.15 %
2.15 %
2.90 %
1.70 %
1.64 %
1.67 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
42.97 %
43.89 %
44.82 %
45.18 %
42.50 %
40.88 %
40.91 %
43.63 %
44.03 %
45.04 %
45.49 %
45.56 %
44.44 %
45.03 %
45.22 %
41.89 %
48.16 %
48.35 %
48.76 %
Others
19.60 %
19.54 %
19.38 %
19.12 %
18.05 %
18.31 %
18.29 %
14.53 %
13.99 %
13.80 %
13.95 %
12.64 %
15.33 %
12.74 %
12.74 %
11.83 %
12.41 %
12.12 %
11.96 %
No of Share Holders
1,65,609
2,30,611
2,44,924
2,55,155
2,60,933
2,83,547
2,87,115
2,87,370
3,06,030
3,06,150
3,01,832
3,04,001
3,04,289
3,36,019
3,48,766
3,52,839
4,30,929
4,48,361
4,68,860

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release21 hours ago
Announcement under Regulation 30 (LODR)-Change in Management1 day ago
Intimation Of Formation Of A Wholly Owned Subsidiary In Dubai United Arab Emirates1 day ago
Launch Of Four New Products5 days ago
Intimation Of Name Change Of Subsidiary CompanyApr 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 31, 2025
Change In Status Of Dr. Morepen Limited - From Wholly Owned Subsidiary To Subsidiary Of The CompanyMar 31, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMar 29, 2025
Closure of Trading WindowMar 27, 2025
Intimation Of Incorporation Of A Step Down Subsidiary CompanyMar 20, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2025
Intimation Of Formation Of A Step Down Subsidiary CompanyFeb 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 12, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 10, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 06, 2025
Statement Of Deviation & Variation - Proceeds Of QIP IssueFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 06, 2025
Results - Q3 FY 25Feb 06, 2025
Board Meeting Outcome for Board Meeting Outcome For Results Q-3 FY 25Feb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Board Meeting Intimation for Q-3 FY 2025 Results.Feb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Update On Disclosure Submitted On 12-August-2024Jan 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 18, 2025
Extra-Ordinary General Meeting Of The Members - To Be Held On Monday February 10 2025Jan 17, 2025
Outcome Of Board Meeting-Hiving Off Medical Devices BusinessJan 14, 2025
Intimation Under Regulation 30 Of Incorporation Of A Subsidiary Company.Jan 08, 2025
Closure of Trading WindowDec 30, 2024
Disclosure under Regulation 30A of LODRDec 27, 2024
Loan AgreementDec 18, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 10, 2024
Disclosure under Regulation 30A of LODRDec 04, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 03, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 22, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 19, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2024
Monitoring Agency Report - QIP IssueNov 11, 2024
Statement Of Deviation & Variation - Proceeds Of QIP IssueNov 11, 2024

Technical Indicators

RSI(14)
Neutral
67.93
ATR(14)
Less Volatile
3.47
STOCH(9,6)
Overbought
82.39
STOCH RSI(14)
Neutral
77.53
MACD(12,26)
Bullish
1.42
ADX(14)
Weak Trend
23.59
UO(9)
Bearish
62.55
ROC(12)
Uptrend But Slowing Down
27.22
WillR(14)
Overbought
-9.91